Saw palmetto (Serenoa repens) is one of the most widely sold botanical ingredients for men’s ageing-related health, and brands abroad ask for a Japan-made saw palmetto product on the strength of decades of use and a large body of clinical research.
This guide is for brand owners planning a saw palmetto product made in Japan. It sets out what the most recent, rigorous evidence shows, why it differs from some older, smaller studies, Japan’s food status for the ingredient, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a saw palmetto product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 2023 Cochrane review of 27 trials found that saw palmetto makes little to no difference to urologic symptom scores or quality of life compared with placebo, a more cautious conclusion than an older, smaller meta-analysis had reached.
| Study | Design/What was analysed | Reported result |
|---|---|---|
| Cochrane systematic review, Cochrane Database of Systematic Reviews 2023 (PMID 37345871) | 27 randomised controlled trials, 4,656 men with symptoms consistent with an enlarged prostate; 19 trials compared saw palmetto with placebo, 8 compared a saw palmetto combination with placebo | High-certainty evidence that saw palmetto results in little to no difference in urologic symptom scores (mean difference -0.90 on a 0–35 scale) or quality of life at short-term follow-up versus placebo; probably little to no difference in adverse events; combination formulas showed a larger score change but with low-certainty evidence |
| Meta-analysis, BJU International 2004 (PMID 15049985) | 14 randomised trials and 3 open-label trials, 4,280 men, of a standardised saw palmetto extract, pooled by random-effects meta-analysis | Reported an improvement in peak urinary flow rate and a reduction in nocturnal urination frequency versus placebo, and a roughly 5-point reduction in symptom score; the authors noted meaningful heterogeneity between trials, with one large two-year trial showing no difference between saw palmetto and placebo pulling the pooled nocturia result down |
Three points worth keeping in view:
- The newer, larger, stricter review found less effect than the older one. The 2023 Cochrane review used sensitivity analyses limited to low-risk-of-bias studies and reached high-certainty conclusions of little to no benefit — a more rigorous standard than the 2004 pooled analysis applied.
- Funding. The 2023 Cochrane review reports that 10 of its 27 included studies were funded by the pharmaceutical industry, 2 by government agencies, and the rest did not specify funding.
- Research population. Both studies enrolled men with lower urinary tract symptoms associated with an enlarged prostate. That is a fact about the research population, and it is not a basis for a disease-linked claim about a supplement sold to the general public.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Saw palmetto fruit sits on the Japanese list of ingredients not judged to be medicines unless a medicinal claim is made, which is why it is sold in Japan as a general food ingredient.
Japan’s food-drug classification system (食薬区分) maintains a list of substances treated exclusively as medicines and a separate list of substances not judged to be medicines provided the product does not claim a medicinal effect. Saw palmetto (ノコギリヤシ, also called ノコギリパルメット), fruit, sits on the non-medicinal list. That status is why saw palmetto extract is widely sold in Japan through ordinary food retail channels, in capsules aimed at men’s ageing-related health.
Being food-usable is a separate question from carrying a notified function. A Japanese company wishing to state a specific function for a saw palmetto product under the Foods with Function Claims system would need its own notification and its own supporting evidence for that exact product.
💬 Need an evidence summary for your regulatory adviser that reflects the newer Cochrane finding honestly? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe saw palmetto by what has been studied, and reflect the newer, more rigorous evidence rather than only the older, more favourable meta-analysis.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied in men for urinary comfort scores; recent Cochrane evidence found little to no difference versus placebo” | Any prostate-condition name, or “treats”, “shrinks” or “cures” anything |
| ”Contains a standardised saw palmetto extract” with the amount per serving | ”Clinically proven” citing only the older, more favourable meta-analysis |
| Naming both the 2023 and 2004 findings if you cite either | Implying a guaranteed improvement in urinary symptoms |
How saw palmetto is formulated
Saw palmetto’s active lipid and sterol compounds are fat-soluble, so most products use a standardised liposterolic extract in a soft or hard capsule.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Soft capsule | Suits an oil-based liposterolic extract | Shell material and oxidation protection |
| Hard capsule | Works with a dried, standardised powder extract | Standardisation method affects potency per capsule |
Decisions that shape the specification:
- Extraction and standardisation. Saw palmetto extracts are typically standardised to a fatty acid and sterol content. Ask the supplier for the extraction method (commonly supercritical CO2 or hexane/ethanol) and the guaranteed specification.
- Amount per serving. Trial doses in the studies above were commonly in the range used by standardised commercial extracts; match your amount to a specific study if you plan to cite one.
- Companion ingredients. Saw palmetto is often combined with pumpkin seed, zinc or other “healthy ageing” ingredients aimed at men. Each companion needs its own check against Japanese food law.
- Your market’s status for saw palmetto. Confirm its status as a food or supplement ingredient in each market you plan to sell in before committing to a formula.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Saw palmetto itself is well established in Japanese foods. Companion ingredients in combined men’s-health formulas are where a check most often turns up a problem. See the Japan-made supplement OEM page, and compare with our zinc and magnesium guides.
Before you ask for a quotation
A factory can quote accurately once the extract standardisation, the amount, the form and the companions are fixed.
- Saw palmetto extraction method and fatty acid/sterol standardisation
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made saw palmetto product? Send us the concept — extract standardisation, amount, form and the countries you will sell in.
Frequently asked questions
1. Does saw palmetto improve urinary symptoms?
The most recent and rigorous evidence, a 2023 Cochrane review of 27 trials, found little to no difference versus placebo in symptom scores or quality of life, with high-certainty evidence. An older, smaller 2004 meta-analysis had reported a benefit; the newer review used stricter methods and a larger dataset.
2. Why do older studies show more benefit than the 2023 Cochrane review?
The 2023 review applied sensitivity analyses limited to trials at low risk of bias and used the GRADE framework to rate certainty. The 2004 meta-analysis, by contrast, pooled a wider range of trial designs and noted meaningful heterogeneity, with one large two-year trial showing no benefit pulling its own pooled result down.
3. Who funded the saw palmetto research?
The 2023 Cochrane review reports that 10 of its 27 included studies were funded by the pharmaceutical industry, 2 by government agencies, and the remainder did not specify funding sources.
4. Is saw palmetto legal to sell as a food in Japan?
Yes. Saw palmetto fruit sits on Japan’s list of ingredients not judged to be medicines unless a medicinal claim is made, which is why it is sold there as a general food ingredient.
5. What form does saw palmetto usually take?
A standardised liposterolic extract in a soft or hard capsule, since its active compounds are fat-soluble.
Sources: “Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement”, Cochrane Database of Systematic Reviews 2023 (PMID 37345871); “Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia”, BJU International 2004 (PMID 15049985); Japan Ministry of Health, Labour and Welfare 食薬区分における成分本質（原材料）の取扱いの例示. Checked on 25 September 2026.